Меню
Набор скоро начнётся NCT07454772

Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis

Фаза I / Фаза II С лечением Granulomatous Mastitis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Steroid, Antibiotic.
Кому может быть актуально
Состояния в реестре: Granulomatous Mastitis. Базовые параметры: Без ограничений · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Индия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis - A Randomized Controlled Trail

Обзор

The goal of this clinical trial is to find the most effective and safe medical treatment for Granulomatous Lobular Mastitis (GLM) - a rare, chronic inflammatory breast disease that affects young and middle-aged women, often following childbirth. The main questions it aims to answer are: Does an antibiotic regimen (clarithromycin, ofloxacin, rifaximin) lead to faster and complete healing (Complete Clinical Response) compared to steroids? Do steroids (prednisolone in tapering doses) provide better symptom control or cause more side effects? Researchers will compare the antibiotic group (Group A) and the steroid group (Group B) to see which treatment results in quicker recovery, fewer side effects, and lower recurrence rates. Participants will: Receive a 14-day antibiotic trial initially (screening phase). If no improvement, be randomly assigned to: Group A (Antibiotic therapy) - Clarithromycin, Ofloxacin, Rifaximin for 8 weeks, or Group B (Steroid therapy) - Prednisolone in tapering doses for 8 weeks. Undergo evaluation after 2 months: If not fully recovered, receive Methotrexate + Folic acid for another 8 weeks. If still no improvement, switch to the alternate treatment or undergo surgery if required. Attend regular follow-ups for 6 months for clinical assessment and monitoring of side effects. This 2-year study aims to develop a standardized, step-by-step treatment protocol for GLM, helping improve outcomes and reduce unnecessary surgeries for affected women.

Подробное описание

What is this study about?

This research is being done at AIIMS Bhubaneswar to find the best medical treatment for a breast condition called Granulomatous Lobular Mastitis (GLM).

GLM is a rare, long-lasting inflammation of the breast that mainly affects young and middle-aged women, often those who have recently had children. It can look very similar to breast cancer or a breast abscess, causing anxiety and sometimes unnecessary surgery.

Common symptoms include:

Painful or painless breast lump

Swelling, redness, or abscess (collection of pus)

Discharge from the nipple or retraction (nipple pulled inward)

Skin changes over the breast It can occur in one or both breasts and may come back after treatment.

Why is this study important?

At present, there is no single, standard treatment for GLM. Doctors use antibiotics, steroids, immunosuppressants (like methotrexate), or surgery - but the results vary widely. Some medicines help one patient but not another, and some cause unwanted side effects or recurrences.

This study aims to compare antibiotics and steroids directly, to identify which gives better and faster healing with fewer side effects. The goal is to develop a clear, step-by-step treatment plan for all patients with GLM.

What will happen in this study? Who can take part?

Women diagnosed with GLM by biopsy (tissue test).

Participants must be willing to attend regular follow-ups.

Women who are pregnant, breastfeeding, diabetic (uncontrolled), on other immunosuppressive treatment, or allergic to study drugs cannot participate.

How the study works:

First step (screening):

All participants will receive a short course of antibiotics for 14 days.

If the infection improves, treatment continues outside the study.

If it doesn't improve, the person will be included in the main trial.

Random assignment:

Patients will be randomly divided into two groups:

Group A - Antibiotic group: Receives clarithromycin, ofloxacin, and rifaximin tablets for 8 weeks.

Group B - Steroid group: Receives prednisolone (steroid tablets) in reducing doses for 8 weeks.

Review after 2 months:

Doctors will check whether the breast swelling and pain are gone.

If completely cured (called Complete Clinical Response or CCR), medicines are stopped.

If not cured, the patient is given an additional medicine (methotrexate + folic acid) for 8 weeks.

If still not improved:

The treatment groups are switched (antibiotic patients receive steroids, and vice versa).

If there's still no recovery, surgery (like abscess drainage or lump removal) will be considered.

Throughout the study, symptoms, side effects, and any need for surgery will be recorded carefully.

How long does participation last?

Each participant will be followed for around 6 months - this includes treatment, monitoring, and follow-up visits.

Possible benefits for participants

Regular medical check-ups, follow-ups, and investigations by specialist doctors.

Chance of receiving an effective, well-monitored treatment plan.

Early detection of complications and quick medical management.

Contribution to medical knowledge that may help future patients avoid prolonged or incorrect treatment.

Possible side effects or risks

Вмешательства

  • Препарат Steroid
    Once randomized into the steroid arm, oral therapy with Tab. Prednisolone 20mg BD will be given for 14days, Tab. Prednisolone 10mg BD will be given for 21 days, Tab. Prednisolone 5mg BD will be given for 14days and Tab. Prednisolone 2.5mg BD will be given for 7 days(tapering dose) will be used in this intervention compared to antibiotics which are used in other. If the rate of response to oral steroids is slow and therapy prolonged, intralesional steroids (Inj. Triamcinalone 40mg) will be given
  • Препарат Antibiotic
    Once randomized into the antibiotic arm, dual oral antibiotic therapy with Ofloxacin 400mg and Clarithromycin 500mg will be used in this intervention compared to steroids which are used in other

Первичные конечные точки

  • Primary outcome [Срок оценки: 2 months]
Вторичные конечные точки (11)
  • To assess the safety and tolerability of each treatment regimen [Срок оценки: 2 months]
  • To assess the the proportion of patients requiring surgery in the treatment of GLM [Срок оценки: 2 months]
  • To assess the role of different quantum of surgery needed (Incision and Drainage/Resection/mastectomy) in the treatment of GLM [Срок оценки: 2 months]
  • To assess the number of patients have recurrence after surgery in the treatment of GLM [Срок оценки: 2 months]
  • To assess the number of patients requiring Aspiration/ minisuction drain(6 french aspiration catheter/pigtail) in the treatment of GLM [Срок оценки: 2 months]
  • To assess the failure rate of aspiration/ minisuction drain(6 french aspiration catheter/pigtail) in the treatment of GLM [Срок оценки: 2 months]
  • To determine the Indications of immunosuppressive therapy in the treatment of GLM [Срок оценки: 2 months]
  • To To determine the proportion of patient requiring combination immunosuppressive therapy in the treatment of GLM [Срок оценки: 2 months]
  • To determine the average duration of immunosuppressive therapy required in the treatment of GLM [Срок оценки: 2 months]
  • Histological pattern (neutrophilic/lymphocytic/mixed) [Срок оценки: 2 months]
  • Proportion of CCR obtained in each histological pattern (neutrophilic/lymphocytic) [Срок оценки: 2 months]

Критерии участия

Критерии включения

  • Women histologically diagnosed with GLM willing to participate in the study and to come for follow up.

Критерии исключения

  • Declining to participate in the study
  • Pregnant or lactating women
  • Patient already on antibiotic/steroid therapy and are responding to treatment
  • Known immunosuppression or diabetes mellitus uncontrolled
  • Patient already on immunosuppression therapy for any other disorder
  • Lost to follow-up before 3 months post-treatment
  • Allergic to one of the antibiotics/steroids which will be used
  • Contraindications to oral steroids therapy
  • Contraindications to methotrexate therapy

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Перекрёстный дизайн
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Индия · 1 центр
  • AIIMS Bhubaneswar — Bhubaneswar

Идентификаторы

NCT: NCT07454772 · ECR/534/inst/OD/2014/RR-25

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗